.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the symbolic representation “BIOA,” depending on to papers filed along with the Securities and also Swap Payment. The business has not publicly discussed an expected monetary quantity for the offering.The clinical-stage business promotes lead candidate azelaprag, an orally supplied tiny particle slated to enter into stage 2 screening in combo along with semaglutide– marketed by Novo Nordisk under trademark name Wegovy for weight management– in the very first half of upcoming year. Semaglutide is actually also marketed as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually made to incorporate effectively along with GLP-1 drugs, boosting weight loss while keeping muscular tissue mass. The investigational medication was actually located to become well-tolerated one of 265 individuals across eight period 1 trials, depending on to BioAge.Recently, BioAge got the assistance of Lilly to operate a trial incorporating azelaprag along with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for weight reduction. The companions are currently conducting a stage 2 trial of azelaprag and also tirzepatide, with topline outcomes anticipated in the third fourth of 2025.The biotech is also organizing an insulin sensitiveness proof-of-concept trial analyzing azelaprag as a monotherapy in the very first one-half of upcoming year to assist possible evidence expansion.
Moreover, the provider prepares to inquire the FDA for approval in the 2nd fifty percent of 2025 to launch individual testing for an NLRP3 prevention targeting metabolic ailments as well as neuroinflammation.BioAge’s anticipated move to everyone market adheres to a slight uptick in considered biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO landscape is a “combined photo,” with high-quality providers still debuting on the general public markets, just in lessened numbers, depending on to PitchBook.